PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25995825-5 2015 In addition, MPO and NFkappaB immunoreactivities in the glial cells were also decreased in the PGZ-treated group. Pioglitazone 95-98 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 21-29 24029145-0 2014 Pioglitazone reduces inflammation through inhibition of NF-kappaB in polymicrobial sepsis. Pioglitazone 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 56-65 25168383-6 2015 Furthermore, immunohistochemical and biochemical analyses demonstrated that the administration of PG suppressed oxidative stress, nuclear factor-kappaB (NFkappaB) signal activation and inflammation both in the spinal cords and skeletal muscles of the SBMA mice. Pioglitazone 98-100 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 153-161 24029145-9 2014 Lung IkappaBalpha protein expression increased and corresponded with a decrease in NF-kappaB activity in the lung from pioglitazone-treated mice. Pioglitazone 119-131 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 83-92 24029145-10 2014 Pioglitazone reduces the inflammatory response in polymicrobial sepsis in part through inhibition of NF-kappaB and may be a novel therapy in sepsis. Pioglitazone 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 101-110 23524568-8 2013 Chronic pioglitazone treatment significantly ameliorated the memory deficits and amyloidogenesis of STZ-induced diabetic mice, and suppressed expression of APP, BACE1, RAGE and NF-kappaB p65, and activated PPARgamma in the hippocampus and cortex. Pioglitazone 8-20 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 177-186 28708885-10 2017 CONCLUSION: Pioglitazone can ameliorate diabetic renal damage, and this effect is related to the inhibition of renal AGE/RAGE axis activation and the down-regulation of NF-kappaB expression. Pioglitazone 12-24 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 169-178 15649489-7 2005 Pioglitazone also reduced iNOS, NFkappa-B, and 3-nitrotyrosine immunoreactivity in the spinal cords of G93A transgenic mice. Pioglitazone 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 32-41 22620268-9 2012 Treatment of PPARgamma agonist, pioglitazone (18 or 9 mg/kg body weight), significantly reversed diabetes-induced impairment of learning and memory behavior, which is involved in decreases of Abeta40/Abeta42 via inhibition of NF-kappaB, BACE1 and RAGE in brain as well as attenuation of hyperglycemia, hyperlipemia, and hypoinsulinemia. Pioglitazone 32-44 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 226-235 18312546-6 2008 Our results suggest that pioglitazone protects motor neurons against p38-mediated neuronal death and NF-kappaB-mediated glial inflammation via a PPARgamma-independent mechanism. Pioglitazone 25-37 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 101-110 14690537-0 2004 Protection by pioglitazone in the MPTP model of Parkinson"s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. Pioglitazone 14-26 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 123-133 14690537-10 2004 Because an increase in inhibitory protein-kappa-Balpha (IkappaBalpha) expression and inhibition of translocation of the nuclear factor kappaB (NFkappaB) subunit p65 to the nucleus in dopaminergic neurons, glial cells and astrocytes correlated with the protective effects of pioglitazone, our results suggest that pioglitazone sequentially acts through PPARgamma activation, IkappaBalpha induction, block of NFkappaB activation, iNOS induction and NO-mediated toxicity. Pioglitazone 274-286 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 143-151 14690537-10 2004 Because an increase in inhibitory protein-kappa-Balpha (IkappaBalpha) expression and inhibition of translocation of the nuclear factor kappaB (NFkappaB) subunit p65 to the nucleus in dopaminergic neurons, glial cells and astrocytes correlated with the protective effects of pioglitazone, our results suggest that pioglitazone sequentially acts through PPARgamma activation, IkappaBalpha induction, block of NFkappaB activation, iNOS induction and NO-mediated toxicity. Pioglitazone 313-325 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 143-151 12144946-7 2002 Rosiglitazone or pioglitazone inhibited increase in phosphorylated I-kappaB (pI-kappaB) expression, as an index of activation of nuclear factor (NF)-kappaB, in both joint tissues and RAW264 cells. Pioglitazone 17-29 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 129-155 11991651-4 2002 Furthermore, overexpression of the coactivator p300 restored BADGE- or pioglitazone hydrochloride-suppressed promoter activity of the nuclear factor-kappa B (NF-kappaB)-luciferase reporter gene, suggesting that PPARgamma may interfere with NF-kappaB transcriptional activity via coactivator competition. Pioglitazone 71-97 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 134-156 11991651-4 2002 Furthermore, overexpression of the coactivator p300 restored BADGE- or pioglitazone hydrochloride-suppressed promoter activity of the nuclear factor-kappa B (NF-kappaB)-luciferase reporter gene, suggesting that PPARgamma may interfere with NF-kappaB transcriptional activity via coactivator competition. Pioglitazone 71-97 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 158-167 11991651-4 2002 Furthermore, overexpression of the coactivator p300 restored BADGE- or pioglitazone hydrochloride-suppressed promoter activity of the nuclear factor-kappa B (NF-kappaB)-luciferase reporter gene, suggesting that PPARgamma may interfere with NF-kappaB transcriptional activity via coactivator competition. Pioglitazone 71-97 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 240-249 33591571-7 2021 Pioglitazone, the activator of PPARgamma, blocked the activation of NFAT/NF-kappaB, reversed the protein expression of SMC phenotypic modulation markers and inhibited cell proliferation, migration, and macrophage adhesion to SMCs in SKI SMCs. Pioglitazone 0-12 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 73-82 23251143-6 2012 Electrophoresis mobility shift assay (EMSA) revealed that activation of translocation of nuclear factor- (NF-) kappaB, which is a suppressor of apoptosis, in the nucleus of the hepatocytes was suppressed in the pioglitazone-treated mice after Con A injection. Pioglitazone 211-223 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 89-117 31509504-10 2019 RESULTS: We observed that activation of PPARgamma by its agonist, pioglitazone, reduces tumor volume, Tlr-4, Myd-88, Nf-kb1 mRNA expression, TLR4 protein expression and TNF-alpha production in melanoma tumor especially in groups that were injected with LPS -stimulated cells. Pioglitazone 66-78 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 117-123